National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

STATUTORY RULES

1965 No. 151

__________

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1964.*

I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1964.

Dated this twenty-first

day of October, 1965.

CASEY

Governor-General.

By His Excellency’s Command,

(Signed) Ian Sinclair

Minister of State for Social Services

acting for and on behalf of the

Minister of State for Health.

________

Amendments of the National Health (Pharmaceutical Benefits) Regulations 

Commencement.

1. These Regulations shall come into operation on the first day of November, 1965.

First Schedule.

2.The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

(a) by omitting the word—

“Calciferol.”;

(b) by omitting the words—

“Chlorcyclizine Hydrochloride.”;

(c) by omitting the word—

“Hydrochlorothiazide.”;

(d) by omitting the words—

“Mustine Hydrochloride.”;

(e) by inserting after the words—

“Nitrous Oxide.”

the words—

“Norethandrolone.

Norethandrolone Tablets.”;

(f) by inserting after the word—

“Noscapine.”

the words—

“Novobiocin Calcium.

Novobiocin Sodium.”;

 

*Notified in the Commonwealth Gazette on 28 October, 1965.

  Statutory Rules 1960, No. 17, as amended to date. For previous amendments of the National Health (Pharmaceutical Benefits) Regulations, see footnote   to Statutory Rules 1965, No. 51 and see also Statutory Rules 1965, No. 51.

11409/ 65.— Price 2s. 6d. (25c)  10/5.10.1965

(g) by omitting the words—

“Piperazine Phosphate”; and

(h) by inserting after the words—

“Undecenoic Acid.”

the words—

“Vancomycin Hydrochloride.

Vancomycin Injection.”.

3. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—

Second Schedule.

(a) by omitting the item relating to the pharmaceutical benefit

“Adrenaline Acid Tartrate, B.P.”;

(b) by omitting the item relating to the pharmaceutical benefit

“Aluminium Hydroxide Gel Dried, B.P.”;

(c) by inserting after the item relating to the pharmaceutical benefit

“Betamethasone Phosphate” the following item:—

“ Calciferol.......................................................... —”;

(d) by inserting after the item relating to the pharmaceutical benefit

“Erythromycin Oral Suspensions” the following item:—

“Erythromycin Paediatric Drops......................... —”;

(e) by omitting the item relating to the pharmaceutical benefit

“Ferrous Gluconate, B.P.”;

(f) by inserting after the item relating to the pharmaceutical benefit

“Framycetin Sulphate” the following item:—

“Fusidic Acid (Diethanolamine Salt).................. —”;

(g) by omitting the item relating to the pharmaceutical benefit

“Magnesium Bicarbonate Solution, B.P. 1948”;

(h) by inserting after the item relating to the pharmaceutical benefit

“Mepyramine Maleate, B.P.” the following item:—

“Methacycline..................................................... —”;

(i) by omitting the item relating to the pharmaceutical benefit

“Paracetamol, B.P.”;

(j) by omitting the item relating to the pharmaceutical benefit

“Sulphadimethoxine, B.P.C.”;

(k) by omitting the item relating to the pharmaceutical benefit

“Sulphamethoxydiazine”;

(l) by omitting the item relating to the pharmaceutical benefit

“Sulphamethoxypyridazine N-Acetyl”; and

(m) by inserting after the item Telating to the pharmaceutical benefit

“Surgical Cement” the following item:—

“Surgical Cement Solvent................................... —”.

Third and Fifth Schedules.

4.The Third and Fifth Schedules to the National Health (Pharmaceutical Benefits) Regulations are repealed and the following Schedules inserted in their stead:—

THIRD SCHEDULE

Regulation 11

Drugs and Medicinal Preparations Additional to the Drugs and Medicinal Preparations in the British Pharmacopoeia

Acetazolamide Sodium.

Acetohexamide.

Acidified Golden Syrup, A.P.F. 1955.

Acriflavine, B.P.C.

Acrylic Resin.

Adrenaline Hydrochloride.

Adrenaline Mucate.

Agar B.P.C. 1954.

Alkavervir.

Aloin B.P.C.

Almond Oil Volatile Bitter, B.P.C. 1959.

Aloxidone.

Aluminium Acetate Solution, B.P.C.

Aluminium Hydroxide Mixture, A.P.F.

Aluminium Hydroxide Mixture, A.P.F. 1955.

Aluminium Sodium Polyhydroxy Mon-ocarbonate Hexitol

 Complex.

Aluminium Sodium Silicate.

Aluminium Powder, B.P.C.

Amaranth Solution, A.P.F.

Amaranth Solution, Compound, A.P.F.

Amaranth Solution, B.P.C.

Aminocaproic Acid.

Amitriptyline Hydrochloride.

Ammonia Aromatic Spirit, B.P.C.

Ammonia Solution Strong, B.P.C.

Ammonium Bicarbonate, B.P.C.

Ammonium Bromide, B.P.C.

Amphotericin B.

Ampicillin.

Antazoline Methanesulphonatc, B.P.C.

Antazoline Sulphate.

Attapulgite.

Aurothioglucose.

Azathioprine.

Beclamide.

Beeswax, Yellow, B.P.C.

Belladonna Suppository, B.P. 1948.

Benedict’s Solution, A.P.F.

Benzalkonium Chloride.

Benzoin, B.P.C.

Benzoinated Lard, B.P.C. 1954.

Benzoin Compound Tincture, B.P.C.

Benzoin Tincture, B.P.C.

Benzylpenicillin in Oil.

Bephenium Hydroxynaphthoate, B.P.C.

Betamethasone.

Betamethasone Disodium Phosphate.

Betamethasone Phosphate.

Bethanidine Sulphate.

Bismuth Subgallate, B.P.C.

Bretylium Tosylate.

Brown Snake Antivenene.

Buchu Concentrated Infusion, B.P.C. 1954.

Butabarbital Sodium.

Butyl Aminobenzoate, B.P. 1953.

Cade Oil, B.P.C.

Caffeine and Sodium Benzoate, B.P.C. 1954.

Caffeine Citrate, B.P.C. 1959.

Cajuput Spirit, B.P. 1948.

Calamine Cream, A.P.F. 1955.

Calcium Aurothiomalate.

Calcium Di-Oxytetracycline.

Calcium Gluconogalactogluconate.

Calcium Lactobionate.

Calcium Phosphate, B.P.C.

Calumba, Concentrated Infusion, B.P. 1948.

Calumba Tincture, B.P. 1948.

Capsicum Ointment, B.P.C.

Capsicum Tincture, B.P.C.

Carbamazepine.

Carbarsone, B.P.C.

Carbinoxamine Maleate.

Cardamom Aromatic Tincture, B.P.C.

Catechu Tincture, B.P.C.

Cetomacrogol Emulsifying Wax, B.P.C.

Cetyl Alcohol Compound.

Chloramine, B.P.C.

Chloramphenicol Palmitate, B.P.C.

Chloramphenicol Stearate.

Chloramphenicol Succinate.

Chlorazanil Hydrochloride.

Chlorhexidine Diacetate.

Chlorhexidine Gluconate.

Chlorobenzol Disulphonamide.

Chlorotrianisene, B.P.C.

Chlorthalidone, B.P.C.

Choline Theophyllinate, B.P.C.

Cinnamon Spirit, B.P.C. 1949.

Cinnamon Water, Concentrated, B.P.C.

Clemizole Hydrochloride.

Clemizole Tannate.

Clopamide.

Clove, Concentrated Infusion, B.P.C. 1954.

Cloxacillin Sodium.

Coal Tar, B.P.C.

Cochineal Tincture, B.P. 1948.

Coconut Oil, B.P.C. 1949.

Codeine, B.P.C. 1954.

Copper Sulphate, B.P.C.

Creosote, B.P.C. 1959.

Cudbear Tincture, A.P.F. 1947.

Curd Soap, B.P.C.

Cyclopenthiazide.

Cyclophosphamide.

Cyclothiazide.

Cycrimine Hydrochloride.

Cymogran.

Cyproheptadine Hydrochloride.

Death Adder Antivenene.

Third Schedule—continued

Demecarium Bromide.

Deoxycortone Glucoside.

Desferrioxamine.

Deslanoside.

Dexamethasone Sodium Phosphate.

Dexchlorpheniramine Maleate.

Dextran.

Dextriferron.

Dicyclomine Hydrochloride, B.P.C.

Digitalis Tincture, B.P.C. 1959.

Dihydroergotamine Methanesulphonate.

Dihydromorphinone Hydrochloride, B.P.C. 1949.

Dihydrostreptomycin Sulphate, B.P. 1958.

Dihydrotachysterol.

Dimethicone, B.P.C.

Diphenylpyraline Hydrochloride.

Dipyridamole.

Disodium Stilboestrol Diphosphate.

Dithiazanine Iodide.

Dyflos, B.P.C.

Ecothiopate Iodide.

Entsufon.

Ephedrine, B.P.C.

Ergot, Liquid Extract, B.P. 1914.

Erythromycin Ethyl Succinate.

Erythromycin Glucoheptonate.

Erythromycin Lactobionate.

Erythromycin Stearate.

Ethanolamine, B.P.C.

Ethanolamine Oleate.

Ether Nitrous Spirit, B.P.C. 1959.

Ethionamide.

Ethosuximide.

Ethoxzolamide.

Ethyl Biscoumacetate, B.P.C.

Ethylidene Dicoumarin.

Ethylnoradrenaline Hydrochloride.

Ethyloestrenol.

Eucalyptol, B.P.C.

Extract of Ox Bile, B.P. 1948.

Ferric Hydroxide.

Ferrous Aminoacetosulphate.

Ferrous Carbonate Saccharated, B.P.C. 1959.

Ferrous Phosphate Compound Syrup, B.P.C.

Ferrous Phosphate with Quinine and Strychnine Syrup, B.P.C.

Ferrous Succinate.

Folinic Acid.

Framycetin Sulphate.

Frusemide.

Fusidic Acid, Diethanolamine Salt.

Fusidic Acid, Sodium Salt.

Galactomin.

Gall and Opium Ointment, B.P.C.

Gelsemium Tincture, B.P.C.

Glucagon Hydrochloride.

Glucose Indicator.

Glycerophosphate Compound Syrup, A.P.F.

Glycopyrronium Bromide.

Goats Milk, dehydrated.

Gramicidin.

 

Hamamelis Dry Extract, B.P.C.

Hamamelis Liquid Extract, B.P.C.

Heparin Retard.

Hexocyclium Methylsulphate.

Honey, Purified, B.P.C.

Hydrargaphen.

Hydrocyanic Acid, Dilute, B.P.C. 1954.

Hydroxybenzoate Compound Powder, A.P.F.

Hydroxyprogesterone Caproate.

Hyoscine Methobromide.

Hypophosphorous Acid, Dilute, B.P.C.

Idoxuridine.

Indomethacin.

Insulin Injection, specially purified.

Insulin Isophane Injection, specially purified.

Insulin Injection, Special P (Pig).

Iodochlorhydroxyquinoline.

Iodoform, B.P.C. 1954.

Iron Aminoates.

Iron Dextran.

Iron Oxide Saccharated.

Iron Sorbitol Complex.

Isoprenaline Hydrochloride.

Isopropamide Iodide.

Isothipendyl Hydrochloride, B.P.C.

Kanamycin Sulphate, B.P.C.

Kitasamycin.

Lanatoside-C.

Lavender Spike Oil, B.P.C.

Lemon Tincture, B.P. 1958.

Lipopancreatin.

Lissapol.

Lobelia Ethereal Tincture, B.P.C.

Lofenalac.

Lypressin.

Magenta, B.P.C.

Magnesium Chloride.

Magnesium Hydroxide, B.P.C.

Mebhydrolin Napadisylate, B.P.C.

Medroxyprogesterone Acetate.

Mercaptomerin Sodium.

Mestanolone.

Metaraminol Bitartrate.

Metformin Hydrochloride.

Methacycline.

Methazolamide.

Methdilazine Hydrochloride.

Methenamine Mandelate.

Methenolone Acetate.

Methotrexate.

Methoxamine Hydrochloride, B.P.C.

Methsuximide.

Methyclothiazide.

Methyldopa.

Methyl Glucamine.

Methylphenobarbitone, B.P.C.

Methylprednisolone Acetate.

Metronidazole, B.P.C.

Minafen.

Morphine Tartrate.

Myrrh Gum, Powdered, B.P.C.

Myrrh Tincture, B.P.C.

Nalidixic Acid.

 

Third Schedule—continued

Nandrolone Decanoate.

Niclosamide.

Nicotinyl Alcohol Tartrate.

Nicoumalone.

Nitromin.

Nux Vomica, Dry Extract, B.P.C.

Oestradiol Dipropionate, B.P.C. 1954.

Oestrone, B.P.C. 1954.

Oily Ophthalmic Vehicle, A.P.F. 1955.

Orange Peel Compound, Concentrated Infusion, B.P.C. 1954.

Orange Peel, Concentrated Infusion, B.P.C.

Orciprenaline Sulphate.

Oxycodone Pectinate.

Oxymel, B.P.C.

Oxymel of Squill, B.P.C.

Oxymesterone.

Oxyphencyclimine Hydrochloride.

Oxyphenonium Bromide.

Oxytocin.

Pancreatin Enzyme, U.S.N.F. XI.

Papaveretum, B.P.C.

Para-Aminosalicylic Acid.

Paraben Ophthalmic Phosphate Buffer, A.P.F. 1955.

Paraben Ophthalmic Vehicle, A.P.F. 1955.

Paraffin Liquid Light, B.P.C.

Paramethasone Acetate.

Pargyline Hydrochloride.

Pectin.

d-Penicillamine Hydrochloride, B.P.C.

Penicillinase.

Penicillin, Benethamine, B.P.C.

Pentaerythritol Tetranitrate, diluted, B.P.C.

Penthienate Methobromide.

Pertussis Vaccine (Haemagglutinin Aluminium

  Phosphate Adsorbed).

Peru Balsam, B.P.C.

Phenazone, B.P.C.

Phenazopyridine Hydrochloride.

Phenethicillin Potassium.

Phenformin Hydrochloride.

Pheniramine Maleate.

Pheniramine Para-Aminosalicylate.

Phenol Ointment, B.P. 1948.

Phenoxymethylpenicillin, Benzathine.

Phenoxymethylpenicillin, Hydrabamine.

Phensuximide.

Phenytoin.

Phthalylsulphacetamide.

Physostigmine, B.P.C.

Pipenzolate Methobromide.

Pituitary (Posterior Lobe) Powdered, B.P.C.

Polythiazide.

Potable Water.

Potassium Chlorate, B.P.C.

Potassium, Effervescent Tablets.

Prednisolone Sodium Hemisuccinate.

Prednisolone Sodium Hemisulphate.

Prednisolone Sodium Phosphate, B.P.C.

Prednisolone Tertiary Butyl Acetate.

Protoveratrine A.

Pumilio Pine Oil, B.P.C.

Pyrazinamide.

Pyridine Aldoxime Methiodide.

Quillaia Tincture, B.P.C.

Quinethazone.

Raspberry Syrup, B.P.C.

Rauwolfia Alkaloids.

Red Back Spider Antivenene.

Rolitetracycline.

Rosemary Oil, B.P.C.

Salicylamide.

Senega, Concentrated Infusion, B.P.C.

Senna Compound Mixture, B.P.C. 1959.

Senna, Concentrated Infusion, B.P.C. 1959.

Senna Fruit Extract (Standardised).

Siberian Fir Oil, B.P.C. 1949.

Silver Protein, B.P.C.

Silver Protein Mild, B.P.C.

Sobee.

Sodium Carbonate Anhydrous, B.P.C.

Sodium Edetate, B.P.C.

Sodium Folate.

Sodium Lactate.

Sodium Nitrite, B.P.C.

Sodium Potassium Tartrate, B.P.C.

Sodium Tauroglycocholate, B.P.C. 1954.

Spearmint Oil, B.P.C.

Spiramycin.

Spironolactone, B.P.C.

Squill Tincture, B.P.C.

Stanolone.

Stanozolol.

Stearic Acid, B.P.C.

Storax, Prepared, B.P.C.

Strophanthus Tincture, B.P. 1948.

Strychnine, B.P.C. 1959.

Sulphacetamide, B.P.C.

Sulphadiazine Sodium, B.P.C.

Sulphadimethoxine, B.P.C.

Sulphaguanidine, B.P.C.

Sulphamerazine, B.P. 1958.

Sulphamethoxydiazine.

Sulphaphenazole, B.P.C.

Sulphapyridine, B.P.C. 1959.

Sulphasalazine.

Sulphathiazole, B.P.C.

Sulphinpyrazone, B.P.C.

Sulphurated Potash, B.P.C.

Sulphuric Acid, Dilute, B.P.C.

Sulphur Sublimed, B.P.C.

Sultiame.

Surgical Cement.

Surgical Cement Solvent.

Sustanon.

Syrup Glucose Liquid, B.P.C.

Tacrine.

Taipan Antivenene.

Tar Ointment, B.P.C. 1959.

Tartrazine, B.P.C. 1954.

Testosterone Oenanthate.

Tetanus Immune Globulin (Human).

Tetracycline.

Thenalidine.

Thenalidine Tartrate.

Theobromine, B.P.C.

 

Third Schedule—continued

Theobromine and Sodium Salicylate, B.P. 1953.

Theophylline Ethanoate of Piperazine.

Thiethylperazine.

Thioridazine.

Thiotepa.

Thyrotrophin.

Tiger Snake Antivenene.

Titanium Dioxide, B.P.C.

Tolu Tincture, B.P.C. 1959.

Tragacanth (Gum Karaya).

Tretamine.

Triamcinolone, B.P.C.

Triamterene.

Tricyclamol Chloride.

Tridihexethyl Chloride.

Triethanolamine, B.P.C

Trimeprazine Tartrate, B.P.C.

Trimustine Hydrochloride.

Trinitrophenol, B.P.C. 1959.

Triprolidine Hydrochloride, B.P.C.

Trolnitrate Phosphate.

Vadrine.

Valerian Ammoniated Tincture, B.P.C.

Vanillin.

Vasopressin Tannate.

Velactin.

Vinblastine Sulphate.

Vincristine Sulphate.

Vinegar of Squill, B.P.C.

Viomycin Pantothenate.

Viprynium Embonate.

Vitamin A.

Vitamin D.

 

________________

FIFTH SCHEDULE

Regulation 14

Pharmaceutical Benefits the Prescribing of Which is Subject to Conditions and Restrictions

Pharmaceutical Benefits	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
Acetylsalicylic Acid Tablets, B.P...........................................................
Soluble Acetylsalicylic Acid Tablets, B.P.
Compound Acetylsalicylic Acid Tablets, A.P.F.	Any disease or condition in a pensioner
Compound Acetylsalicylic Acid Tablets, B.P.C.
Soluble Compound Acetylsalicylic Acid Tablets
Acrylic Resin..........................................................	Ileostomy or colostomy conditions
Alkavervir..........................................................	Hypertensive crises
Aminocaproic Acid..........................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital.
Amitriptyline Hydrochloride..........................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital.
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride or Imipramine Hydrochloride

Fifth Schedule—continued

Pharmaceutical Benefits	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
Amphotericin B................................	Systemic fungal infection
Ampicillin Capsules.........................	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Ampicillin is the only appropriate antibiotic
Ampicillin Injections........................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Ampicillin Tablets............................
Aneurine Hydrochloride Tablets, B.P.	Any disease or condition in a pensioner
Ascorbic Acid Tablets, B.P...............
Azathioprine....................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Beclamide.......................................
Bemegride Injection, B.P..................	As an antidote to barbiturate and other hypnotic poisons
Betamethasone Tablets.....................	With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets
Betamethasone Disodium Phos-phate Injection	Intra-articular use
Bethanidine Sulphate........................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Busulphan Tablets, B.P.....................	Leukaemia
Calciferol Tablets, B.P......................	Any disease or condition in a pensioner With the written authority of the Director-General—
Calciferol, B.P..................................	Hypoparathyroidism
Chronic hypoparathyroid tetany
Vitamin D-resistant rickets
Calcium Aminosalicylate..................	Tuberculosis
Calcium Gluconogalactogluconate Effervescent Tablets	Hypoparathyroidism
Caramiphen Tablets, B.P...................	Parkinsonism
Carbamazepine.................................	Epilepsy
Trigeminal neuralgia
Chlorambucil Tablets, B.P................	Malignant lymphoma and related conditions
Chloramine Deodorant Tablets and Powder	Ileostomy or colostomy conditions
Chloramphenicol Capsules, B.P.........	Bacterial meningitis
Haemophilus influenzae infections
Intra-ocular infections
Rickettsial infections
Salmonella septicaemia
Typhoid and paratyphoid
Other serious infections sensitive only to Chloramphenicol
Chloramphenicol Injections...............	A disease or condition specified in this column in relation to Chloramphenicol Capsules
Chloramphenicol Tablets..................
Chloramphenicol Oral Suspension.....
Chlorotrianisene Tablets...................	Carcinoma of the prostate
Chlorpromazine Hydrochloride.........	Any disease or condition in a pensioner
Any disease or condition in a patient receiving treatment in or at an approved hospital
With the written authority of the Director-General—
Late-stage malignancy
Radiation sickness

Fifth Schedule—continued

Pharmaceutical Benefits	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride or Imipramine Hydrochloride
Chlortetracycline Capsules, B.P.........	Brucellosis
Herpes zoster ophthalmicus
Intestinal amoebiasis
Leptospirosis

Lymphogranuloma venereum
Psittacosis
Rickettsial infections
Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins.
Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur
Chlortetracycline Hydrochloride Granules	A disease or condition specified in this column in relation to Chlortetracycline Capsules
Choline Theophyllinate.....................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Cloxacillin Sodium...........................
Compound Codeine Tablets, B.P.......
Compound Codeine Soluble Tablets, B.P.
Codeine Phosphate with Acetylsalicylic Acid Soluble Tablets.....................
Codeine Phosphate with Acetylsalicylic Acid Tablets	Any disease or condition in a pensioner
Codeine Phosphate with Acetylsalicylic Acid and Phenacetin Tablets..........
Codeine Phosphate with Acetylsalicylic Acid, Phenacetin and Caffeine Tablets.........................................
Cod Liver Oil Emulsion...................	Any disease or condition in a child under the age of twelve years or in a pensioner
With the written authority of the Director-General—
Corticotrophin Injection, B.P............	A disease or condition specified in this column in relation to Cortisone Injection
Corticotrophin Gelatin Injection, B.P.	Hypsarrhythmia
Corticotrophin Zinc Hydroxide Injection, B.P...............................	Salaam convulsions
The prevention of side effects of corticosteroid therapy
Cortisone Injection, B.P...................	With the written authority of the Director-General—
Anaemia, acquired hacmolytic
Addison’s disease
Adrenocortical hypoplasia
Adrenalectomy, total
Adrenogenital syndrome

Fifth Schedule—continued

Pharmaceutical Benefits	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
Cortisone Injection, B.P.-continued	Agranulocytosis
Behcet’s syndrome
Cranial arteritis
Cushing’s syndrome, including hyperadrenocorticalism
Dematitis, acute exfoliative
Dermatomyositis
Encephalomyelitis
Encephalomyelitis, acute disseminated
Guillain-Barré syndrome
Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis
Hansen’s disease
Hepatitis, progressive or continuing, proven by biopsy or biochemistry
Hodgkin’s disease
Idiopathic hypercalcaemia
Inflammatory conditions of the uveal tract and retina
Keratoplasty
Leucine-sensitive hypoglycaemia
Leukaemia
Lymphosarcoma and follicular lymphoma
Metastatic breast cancer
Mycosis fungoidcs
Nephrosis or nephrotic syndrome
Neuromyelitis optica
Optic neuritis following removal of tumor of the brain
Panhypopituitarism
Pemphigus
Periarteritis nodosa
Progressive transverse myelitis
Pseudohermaphroditism
Purpura, Henoch’s
Purpura, thrombocytopenic
Regional ileitis (Crohn’s disease)
Reticulum cell sarcoma
Rheumatic carditis, acute
Sarcoidosis
Scleroderma
Severe reactions of the skin and mucosa following X-ray therapy
Splenic neutropenia
Status asthmaticus
Steroid therapy prior to operation in patients under steroid therapy
Stevens-Johnson syndrome
Still’s disease in a child under the age of sixteen years
Sympathetic ophthalmitis
Systemic lupus erythematosus
Temporal arteritis
Tropical and non-tropical sprue and all forms of malabsorption associated with those diseases
Type II Nephritis
Ulcerative colitis proven by sigmoidoscopy or radiological report
Cortisone Tablets, B.P......................	With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection

Fifth Schedule—continued

Pharmaceutical Benefits

Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act

Cyanocobalamin Injection, B.P. (other than 1,000 microgram strength)

Established megalocytic anaemia

Cyanocobalamin Injection, B.P. (1,000 microgram strength)

Neuroblastoma

Subacute combined degeneration of the cord

Cymogran........................................

With the written authority of the Director-General, phenylketonuria

Cycloserine, B.P..............................

Any disease or condition in a patient receiving treatment in or at an approved hospital

Cycloserine Capsules, B.P................

Dapsone Tablets, B.P.......................

Hansen’s disease

Demethylchlortetracycline Capsules, B.P.

A disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus

Pemethylchlortetracycline Hyd-rochloride Oral Paediatric Drops and Oral Suspension

Deodorant Detergent Solution (Lis-sapol with Spearmint Oil and Cetrimide)

Ileostomy or colostomy conditions

Deoxycortone Aqueous Injections

Deoxycortone Acetate Injection, B.P.

Deoxycortone Trimethylacetate Injection, B.P.

Addison’s disease Adrenalectomy,

total

Deoxycortone Acetate Implants, B.P.

Deoxycortone Acetate Tablets..........

Desferrioxamine..............................

Any disease or condition in a patient receiving treatment in or at an approved hospital

Dexamethasone Tablets, B.P.............

With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets

Dexamethasone Sodium Phosphate Injections

Intra-articular use

Dienoestrol Cream...........................

Any disease or condition in a pensioner

Dienoestrol Tablets, B.P...................

Carcinoma of the prostate

Mammary carcinoma

Any disease or condition in a pensioner

Dihydrostreptomycin Sulphate Injection

As an alternative to Streptomycin Sulphate in the case of a person who is being treated for a disease or condition specified in this column in relation to Streptomycin Sulphate and who is allergic to Streptomycin Sulphate

Dihydrotachysterol...........................

Parathyroid deficiency

Diiodohydroxyquinoline Vaginal Tablet

Trichomonal or monilial vaginitis

Diiodohydroxyquinoline Effervescent Gynaecological Pessary

Diloxanide Furoate Tablets, B.P........

Amoebic dysentery

Dimethicone....................................

Ileostomy or colostomy conditions

Disodium Stilboestrol Diphosphate

Carcinoma of the prostate

Dithiazanine Iodide..........................

Infestations of Trichuris trichiura or Strongyloides stercoralis

Ditophal..........................................

Any disease or condition in a patient receiving treatment in or at an approved hospital

Erythromycin...................................

Staphylococcal septicaemia or pneumonia

Any gram-positive bacterial infections where these cannot be treated safely and effectively by sulphonamides or penicillins

Ethinyloestradiol Tablets, B.P...........

Turner’s syndrome

Pre-menopausal castration syndrome

Any disease or condition in a pensioner

Ethionamide....................................

Tuberculosis

Fifth Schedule—continued

Pharmaceutical Benefits	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
Ethisterone Tablets, B.P....................	Turner’s syndrome
Ethyloestrenol..................................	With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis
Fludrocortisone Tablets, B.P.............	Addison’s disease
Adrenocortical hypoplasia
Fluoxymesterone Tablets, B.P...........	Castration syndrome (male and female)
Mammary carcinoma
With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis
Folic Acid Injection..........................	Macrocytic anaemia
Folic Acid Tablets, B.P.....................	Sprue or the sprue-like syndrome
Folinic Acid.....................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Framycetin Sulphate Tablets.............	Bowel sterilization preparatory to major surgery.
Fusidic Acid (Sodium Salt or Diethanolamine Salt)........................	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Fusidic Acid (Sodium Salt or Diethanolamine Salt) is the only appropriate antibiotic.
Galactomin......................................	With the written authority of the Director-General, galactosaemia
Goats Milk, dehydrated....................	With the written authority of the Director-General, cows milk allergy in children under the age of four years
Griseofulvin Tablets, B.P..................	With the written authority of the Director-General, for use in severe tinea infections due to Microsporum, Trichophyton or Epidermophyton species which have been proven by laboratory examination
Halibut Liver Oil Capsules...............	Any disease or condition in a pensioner
Hexachlorophane with Entsufon........	Any disease or condition in a patient receiving treatment in or at an approved hospital
Hexachlorophane with Lissapol........
Hexachlorophane in Soap Solution
Hydrocortisone Injection..................	With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection
Hydrocortisone Acetate Injection, B.P.	Intra-articular use
Hydrocortisone Sodium Succinate Injection	Acute adrenal failure due to medical or surgical crises
Stevens-Johnson syndrome
Hydrocortisone Sodium Succinate Soluble Tablet	With the written authority of the Director-General, ulcerative colitis proven by sigmoidoscopy or radiological report
Hydroxocobalamin Injection, B.P. (100 microgram strength)	Established megalocytic anaemia
Hydroxocobalamin Injection, B.P. (1,000 microgram strength)	Neuroblastoma
Sub-acute combined degeneration of the cord
Hydroxyprogesterone Caproate.........	Habitual abortion
Imipramine Tablets, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital

Fifth Schedule—continued

Pharmaceutical Benefits	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
Imipramine Tablets, B.P.—continued	The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride or Imipramine Hydrochloride
Indomethacin...................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Isoniazid Tablets, B.P.......................	Tuberculosis
Kanamycin Sulphate.........................	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the only appropriate antibiotic
Kitasamycin.....................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Levorphanol Tartrate........................	Obstetrical use
Severe intractable pain
Liothyronine Tablets, B.P.................	Myxoedema
Myxoedema coma
Lipopancreatin.................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Lofenalac	With the written authority of the Director-General, phenylketonuria
Medroxyprogesterone Acetate...........	Endometrial carcinoma
Mercaptopurine Tablets, B.P.............	Allergic angiitis
Leukaemia
Lupus erythematosus
Periarteritis
Mestanolone....................................	Mammary carcinoma
With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis
Methacycline...................................	A disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus
Methandienone Tablets, B.P..............	With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis
Methenolone Acetate........................
Methicillin Sodium...........................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Methicillin Injection, B.P..................
Methotrexate Tablets........................	Leukaemia and neoplastic disease
Methotrexate Injections....................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Minafen...........................................	With the written authority of the Director-General, phenylketonuria
Morphine Sulphate, B.P. with Tacrine Tablets..........................................	Severe intractable pain
Mustine Hydrochloride Injection	Malignant lymphoma and related conditions
Nalidixic Acid	Any disease or condition in a patient receiving treatment in or at an approved hospital

Fifth Schedule—continued

Pharmaceutical Benefits	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
Nandrolone Phenylpropionate Injection, B.P.	With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis
Nandrolone Decanoate.....................
Neomycin Sulphate Tablets..............	Bowel sterilization preparatory to major surgery
Nicotinic Acid Tablets, B.P..............	Any disease or condition in a pensioner
Nitrofurantoin Tablets, B.P...............	Urinary tract infections
Nitrofurantoin Oral Suspension.........
Nitromin..........................................	Malignant lymphoma and related conditions
Nystatin...........................................	Proven monilia infections
Orciprenaline Sulphate Injection.......	Any disease or condition in a patient receiving treatment in or at an approved hospital
Orciprenaline Sulphate Solution for Inhalation.....................................
Oxycodone Pectinate........................	Late-stage malignancy
Oxymesterone.................................	With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis.
Oxytetracycline Hydrochloride Capsules.......................................	A disease or condition specified in this column in relation to Chlortetracycline Capsules except herpes zoster ophthalmicus
Oxytetracycline Tablets, B.P.............
Oxytetracycline Hydrochloride Injections.....................................
Calcium di-Oxytetracycline Oral Suspension
Calcium di-Oxytetracycline Paediatric Drops
Oxytocin Nasal Spray......................	Induction of labour
Pancreatin, B.P................................	Fibrocystic disease
Pancreatin Enzyme U.S.N.F. XI........	Pancreatico-duodenectomy
Pancreatic steatorrhoea
Para-Aminosalicylic Acid................	Tuberculosis
Paracetamol Suspension...................	Any disease or condition in a pensioner.
Paracetamol Tablets, B.P..................
Paramethasone Acetate....................	With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection
Paraffin Liquid Emulsion.................	Any disease or condition in a pensioner
Paraffin Liquid Emulsion with Phenolphthalein............................
Pargyline Hydrochloride..................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Penicillamine..................................	With the written authority of the Director-General, Wilson’s disease (hepatolenticular degeneration)
Peritoneal Dialysis Solution.............	Any disease or condition in a patient receiving treatment in or at an approved hospital
Pethidine Hydrochloride with Levallorphan Tartrate	Obstetrical use
Benzylpenicillin with Streptomycin Sulphate	Endocarditis due to Streptococcus faecalis or Streptococcus viridans
Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate
Phenacetin with Codeine Phosphate and Pentobarbitone Sodium	Any disease or condition in a pensioner
Phytomenadione Injection, B.P.........	Antidote to anticoagulants
Pituitary, Posterior Lobe, Insufflation	Diabetes insipidus
Polymyxin B. Sulphate Injection.......	Any disease or condition in a patient receiving treatment in or at an approved hospital

Fifth Schedule—continued

Pharmaceutical Benefits	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
Prednisolone Sodium Phosphate Retention Enema	With the written authority of the Director-General, ulcerative colitis proven by sigmoidoscopy or radiological report
Prednisolone Tablets, B.P..................	With the written authority of the Director-General—
Nodular non-suppurative panniculitis (Christian-Weber disease)
A disease or condition specified in this column in relation to Cortisone Injection except total adrenalectomy, Addison’s disease or adrenocortical hypoplasia
Prednisolone Acetate Injection..........
Prednisolone Methyl Acetate Injections
Prednisolone Tertiary Butyl Acetate Injections	Intra-articular use
Prednisolone Trimethylacetate Injections
Methylprednisolone Tablets, B.P.......
Methylprednisolone Capsules............	With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets
Prednisolone with Magnesium Trisilicate and Dried Aluminium Hydroxide Gel
Prednisolone Sodium Hemisuccinate	With the written authority of the Director-General, medical or surgical crises
Prednisone Tablets, B.P....................	With the written authority of the Director General, a disease or condition specified in this column in relation to Prednisolone Tablets
Prednisone with Magnesium Trisilicate and Dried Aluminium Hydroxide Gel.....................................................
Progesterone....................................	Habitual abortion
Protoveratrine A...............................	Hypertensive crises
Pyrazinamide...................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Pyridostigmine Injection, B.P............	Myasthenia gravis
Pyridostigmine Tablets, B.P..............

Pyridoxine Hydrochloride Tablets	Peripheral neuritis due to isoniazid therapy
Radiation sickness
Riboflavine Tablets...........................	Any disease or condition in a pensioner
Senna Fruit Extract (Standardised)
Sobee...............................................	With the written authority of the Director-General—
Galactosaemia
Lactose intolerance
Milk allergy in children under the age of four years
Sodium Aminosalicylate Tablets B.P.	Tuberculosis
Sodium Aminosalicylate Injection
Sodium Aminosalicylate Cachets
Sodium Aminosalicylate Granules
Sodium Folate..................................	Macrocytic anaemia
	Sprue or the sprue-like syndrome
Spiramycin.......................................	A disease or condition specified in this column in relation to Erythromycin
Spironolactone.................................	With the written authority of the Director-General, to supplement other diuretics when these have proved inadequate.
Stanolone.........................................	Mammary carcinoma
With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis
Stanozolol........................................	With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis

Fifth Schedule—continued

Pharmaceutical Benefits	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
Stilboestrol Injection.........................	Carcinoma of the prostate
Stilboestrol Tablets, B.P....................	Mammary carcinoma
Any disease or condition in a pensioner
Streptomycin Sulphate Injections.......	Bacillary dysentery that is resistant to the Sulphonamides
Brucellosis
Chancroid
Endocarditis due to Streptococcus faccalis or Streptococcus viridans
Friedlander bacillus infections
Haemophilus influenzae infections
Plague
Pseudomonas pyocyanea infections
Rat-bite fever (Streptobacillus moniliformis)
Salmonella infections
Surgical conditions of the bowel (pre-operative and post-operative)
Surgical conditions of the thoracic organs
Tuberculosis
Tularaemia
Urinary tract infections that are resistant to the Sulphonamides
Sulphasalazine..................................	Ulcerative colitis
Sultiame...........................................	For use where other anticonvulsants have failed
Surgical Cement................................	Ileostomy or colostomy conditions
Surgical Cement Solvent...................
Sustanon...........................................
Testosterone Implants, B.P................	Castration syndrome (male and female)
Testosterone Oenanthate....................	Klinefelter Reifenstein Albright syndrome
Testosterone Propionate Injection, B.P.	Mammary carcinoma
Methyltestosterone Tablets, B.P.........
Methyltestosterone, B.P....................
Tetanus Immune Globulin (Human)	With the written authority of the Director-General, where patients are known to be sensitive to horse serum and cattle serum.
Tetracycline Capsules, B.P................
Tetracycline Tablets, B.P..................
Tetracycline Injections......................
Tetracycline Hydrochloride, with a buffering agent—Capsules and Injection........................................	A disease or condition specified in this column in relation to Chlortetracycline Capsules except herpes zoster ophthalmicus
Rolitetracycline................................
Tetracycline Granules.......................
Tetracycline Paediatric Drops............
Tetracycline Oral Suspension............
Tetracycline with a buffering agent—Paediatric Drops.............................
Tetracycline with a buffering agent—Oral Suspension
Broad spectrum antibiotic therapy of premature infants, of patients under steroid therapy or of cases complicated by intestinal moniliasis
	Tetracycline with a buffering agent and Amphotericin B..............................
A second or repeated course of broad spectrum antibiotic therapy for a disease or condition specified in this column in relation to Chlortetracycline Capsules except herpes zoster ophthalmicus
	Tetracycline with a buffering agent and Nystatin

Fifth Schedule—continued

Pharmaceutical Benefits	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
Thiambutosine Tablets, B.P...............	Hansen’s disease
Any disease or condition in a pensioner
Any disease or condition in a patient receiving treatment in or at an approved hospital
With the written authority of the Director-General—
Late-stage malignancy
Radiation sickness
Thioridazine Tablets, B.P...................	With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
Thioridazine.....................................
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride or Imipramine Hydrochloride
Thyrotrophin.....................................	Any disease in or condition in a patient receiving treatment in or at an approved hospital
Tragacanth (Gum Karaya).................	Ileostomy or colostomy conditions
Tretamine.........................................	Malignant lymphoma and related conditions
Triamcinolone...................................	With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets
Trifluoperazine Tablets, B.P..............	Any disease or condition in a pensioner
Any disease or condition in a patient receiving treatment in or at an approved hospital
With the written authority of the Director-General—
Late-stage malignancy
Radiation sickness
With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital
The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride or Imipramine Hydrochloride
Trimetaphan Injection, B.P................	Hypotensive for anaesthesia
Vadrine............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Vasopressin Nasal Spray...................	Diabetes insipidus
Velactin............................................	With the written authority of the Director-General—
Galactosaemia
Lactose intolerance
Milk allergy in children under the age of four years

Fifth Schedule—continued

Pharmaceutical Benefits	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
Vinblastine Sulphate........................	Hodgkin’s disease
Viomycin Sulphate..........................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Viomycin Sulphate Injection, B.P.
Tuberculosis
Viomycin Sulphate with Viomycin Pantothenate
Vitamin A with Aneurine Hydro-
chloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D	Any disease or condition in a pensioner

                             

_________________

By Authority: A. J. Arthur, Commonwealth Government Printer, Canberra.